(OLMA) Olema Pharmaceuticals - Ratings and Ratios
Estrogen Receptor Antagonist, Selective ER Degrader, KAT6 Inhibitor
OLMA EPS (Earnings per Share)
OLMA Revenue
Description: OLMA Olema Pharmaceuticals
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for womens cancers, particularly breast cancer. Their lead product, palazestrant, is an estrogen receptor antagonist and degrader in Phase 3 clinical trials for treating estrogen receptor-positive, HER2-negative breast cancer. The company is also developing OP-3136, a KAT6 inhibitor, in Phase 1 clinical trials for ER+/HER2- metastatic breast cancer.
From a strategic perspective, Olemas focus on womens cancers and specifically on ER+/HER2- breast cancer positions them in a significant market. The development of palazestrant in combination with other therapies (e.g., CDK4/6 inhibitors, PI3Kα inhibitors, and mTOR inhibitors) indicates a comprehensive approach to tackling resistance and improving treatment outcomes. Key Performance Indicators (KPIs) to watch include the progression of palazestrant through Phase 3 trials, the efficacy and safety data from these trials, and the potential for FDA approval.
Analyzing Olemas market potential, the global breast cancer therapeutics market is expected to grow significantly, driven by the increasing prevalence of breast cancer and the demand for effective treatments. Olemas market cap of $310.63M USD suggests a moderate level of investor confidence. However, the absence of a P/E ratio and a negative RoE of -42.31 indicate that the company is not yet profitable, which is typical for a clinical-stage biotech firm with significant R&D expenses. Investors should monitor the companys cash burn rate, upcoming clinical trial results, and potential partnerships or collaborations that could impact their financials and stock performance.
To evaluate Olemas stock (OLMA), one should consider both the technical and fundamental data. While the current stock price is $4.99, with a 52-week range of $3.06 to $16.46, indicating volatility, the SMA20 and SMA50 suggest a relatively stable short-term trend. However, the SMA200 at $6.73 indicates a longer-term downtrend. Investors should watch for changes in these trends, the companys progress in clinical trials, and any regulatory updates that could significantly impact the stock price.
OLMA Stock Overview
| Market Cap in USD | 520m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-11-19 |
OLMA Stock Ratings
| Growth Rating | -2.35% |
| Fundamental | 28.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -46.7% |
| Analyst Rating | 4.63 of 5 |
OLMA Dividends
Currently no dividends paidOLMA Growth Ratios
| Growth Correlation 3m | 90.6% |
| Growth Correlation 12m | -58.5% |
| Growth Correlation 5y | -34.2% |
| CAGR 5y | 38.08% |
| CAGR/Max DD 3y | 0.46 |
| CAGR/Mean DD 3y | 1.31 |
| Sharpe Ratio 12m | 0.19 |
| Alpha | 0.20 |
| Beta | 0.000 |
| Volatility | 78.77% |
| Current Volume | 695.2k |
| Average Volume 20d | 921.4k |
| Stop Loss | 7.2 (-7.1%) |
| Signal | -0.43 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-142.3m TTM) > 0 and > 6% of Revenue (6% = 21.8k TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA 5.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 91.9k% (prev 11.4k%; Δ 80.5kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.33 (>3.0%) and CFO -127.2m > Net Income -142.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (85.5m) change vs 12m ago 51.91% (target <= -2.0% for YES) |
| Gross Margin -11.26% (prev 80.89%; Δ -92.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.11% (prev 0.74%; Δ -0.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -15.44
| (A) 0.88 = (Total Current Assets 367.7m - Total Current Liabilities 33.2m) / Total Assets 382.0m |
| (B) -1.33 = Retained Earnings (Balance) -509.3m / Total Assets 382.0m |
| warn (B) unusual magnitude: -1.33 — check mapping/units |
| (C) -0.34 = EBIT TTM -109.3m / Avg Total Assets 318.3m |
| (D) -13.84 = Book Value of Equity -509.0m / Total Liabilities 36.8m |
| Total Rating: -15.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.97
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -64.32% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.04 = -2.50 |
| 6. ROIC - WACC (= -38.80)% = -12.50 |
| 7. RoE -42.59% = -2.50 |
| 8. Rev. Trend 3.44% = 0.26 |
| 9. EPS Trend 54.29% = 2.71 |
What is the price of OLMA shares?
Over the past week, the price has changed by -0.77%, over one month by +34.55%, over three months by +93.27% and over the past year by -36.84%.
Is Olema Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OLMA is around 7.18 USD . This means that OLMA is currently overvalued and has a potential downside of -7.35%.
Is OLMA a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the OLMA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25 | 222.6% |
| Analysts Target Price | 25 | 222.6% |
| ValueRay Target Price | 7.8 | 1.2% |
Last update: 2025-09-10 04:44
OLMA Fundamental Data Overview
CCE Cash And Equivalents = 361.9m USD (Cash And Short Term Investments, last quarter)
P/B = 1.5069
Beta = 1.935
Revenue TTM = 364.0k USD
EBIT TTM = -109.3m USD
EBITDA TTM = -108.9m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 1.15m USD (from shortTermDebt, last quarter)
Debt = 4.15m USD (Calculated: Short Term 1.15m + Long Term 3.00m)
Net Debt = -50.7m USD (from netDebt column, last quarter)
Enterprise Value = 162.5m USD (520.2m + Debt 4.15m - CCE 361.9m)
Interest Coverage Ratio = unknown (Ebit TTM -109.3m / Interest Expense TTM 0.0)
FCF Yield = -64.32% (FCF TTM -104.5m / Enterprise Value 162.5m)
FCF Margin = -28.7k% (FCF TTM -104.5m / Revenue TTM 364.0k)
Net Margin = -39.1k% (Net Income TTM -142.3m / Revenue TTM 364.0k)
Gross Margin = -11.26% ((Revenue TTM 364.0k - Cost of Revenue TTM 405.0k) / Revenue TTM)
Tobins Q-Ratio = -0.32 (set to none) (Enterprise Value 162.5m / Book Value Of Equity -509.0m)
Interest Expense / Debt = 31.69% (Interest Expense 1.32m / Debt 4.15m)
Taxrate = 21.0% (US default)
NOPAT = -109.3m (EBIT -109.3m, no tax applied on loss)
Current Ratio = 11.09 (Total Current Assets 367.7m / Total Current Liabilities 33.2m)
Debt / Equity = 0.01 (Debt 4.15m / last Quarter total Stockholder Equity 345.2m)
Debt / EBITDA = -0.04 (Net Debt -50.7m / EBITDA -108.9m)
Debt / FCF = -0.04 (Debt 4.15m / FCF TTM -104.5m)
Total Stockholder Equity = 334.1m (last 4 quarters mean)
RoA = -37.25% (Net Income -142.3m, Total Assets 382.0m )
RoE = -42.59% (Net Income TTM -142.3m / Total Stockholder Equity 334.1m)
RoCE = -32.41% (Ebit -109.3m / (Equity 334.1m + L.T.Debt 3.00m))
RoIC = -32.63% (NOPAT -109.3m / Invested Capital 334.9m)
WACC = 6.17% (E(520.2m)/V(524.4m) * Re(6.02%)) + (D(4.15m)/V(524.4m) * Rd(31.69%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 7.14%
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -104.5m)
EPS Correlation: 54.29 | EPS CAGR: 10.89% | SUE: -0.46 | # QB: 0
Revenue Correlation: 3.44 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for OLMA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle